2.97
price down icon6.60%   -0.21
pre-market  Pre-market:  2.98   0.010   +0.34%
loading
C 4 Therapeutics Inc stock is traded at $2.97, with a volume of 924.92K. It is down -6.60% in the last 24 hours and down -24.62% over the past month. C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
See More
Previous Close:
$3.18
Open:
$3.15
24h Volume:
924.92K
Relative Volume:
0.87
Market Cap:
$209.65M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-1.1124
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-9.17%
1M Performance:
-24.62%
6M Performance:
-49.23%
1Y Performance:
-62.78%
1-Day Range:
Value
$2.97
$3.25
1-Week Range:
Value
$2.97
$3.375
52-Week Range:
Value
$2.97
$11.88

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
Name
C 4 Therapeutics Inc
Name
Phone
(617) 231-0700
Name
Address
490 ARSENAL WAY, WATERTOWN
Name
Employee
145
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CCCC
C 4 Therapeutics Inc
2.97 209.65M 20.76M -132.49M -108.55M -2.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.11 118.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.00 74.34B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
639.00 38.83B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.00 32.36B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.75 29.43B 3.30B -501.07M 1.03B -2.1146

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-19-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Equal-Weight
Jan-29-24 Upgrade JP Morgan Underweight → Neutral
Dec-13-23 Upgrade Stifel Hold → Buy
Feb-24-23 Upgrade Credit Suisse Underperform → Neutral
Feb-24-23 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade JP Morgan Overweight → Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Apr-28-22 Initiated Credit Suisse Underperform
Apr-11-22 Downgrade BofA Securities Buy → Neutral
Mar-10-22 Initiated JP Morgan Overweight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Equal Weight
Nov-23-21 Initiated BofA Securities Buy
Oct-14-21 Initiated SVB Leerink Mkt Perform
Sep-30-21 Initiated Stifel Hold
Jun-04-21 Initiated H.C. Wainwright Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Oct-28-20 Initiated UBS Buy
Oct-27-20 Initiated BMO Capital Markets Outperform
Oct-27-20 Initiated Jefferies Buy
View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

pulisher
12:12 PM

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat

12:12 PM
pulisher
Feb 18, 2025

C4 therapeutics chief business officer Scott Boyle sells shares worth $3,650 - Investing.com India

Feb 18, 2025
pulisher
Feb 17, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Feb 17, 2025
pulisher
Feb 14, 2025

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 14, 2025
pulisher
Feb 14, 2025

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 14, 2025
pulisher
Feb 14, 2025

C4 Therapeutics stock plunges to 52-week low of $3.24 - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

UBS Downgrades C4 Therapeutics to Neutral From Buy, Adjusts Price Target to $4 From $18 - Marketscreener.com

Feb 14, 2025
pulisher
Feb 13, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 13, 2025
pulisher
Feb 13, 2025

C4 Therapeutics (CCCC) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 12, 2025
pulisher
Feb 12, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com

Feb 12, 2025
pulisher
Feb 11, 2025

C4 Therapeutics stock plunges to 52-week low of $3.24 By Investing.com - Investing.com Australia

Feb 11, 2025
pulisher
Feb 10, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 10, 2025
pulisher
Feb 10, 2025

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 10, 2025
pulisher
Feb 07, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 07, 2025
pulisher
Feb 07, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 07, 2025
pulisher
Feb 07, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 07, 2025

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 07, 2025
pulisher
Feb 06, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 06, 2025
pulisher
Feb 04, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 04, 2025
pulisher
Feb 04, 2025

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 04, 2025
pulisher
Feb 04, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 04, 2025
pulisher
Feb 04, 2025

C4 Therapeutics stock hits 52-week low at $3.38 - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 04, 2025
pulisher
Feb 04, 2025

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Feb 04, 2025
pulisher
Feb 03, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Marketscreener.com

Feb 03, 2025
pulisher
Feb 03, 2025

Morgan Stanley's Strategic Acquisition of C4 Therapeutics Inc Sh - GuruFocus.com

Feb 03, 2025
pulisher
Feb 03, 2025

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 03, 2025
pulisher
Feb 03, 2025

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2025
pulisher
Feb 03, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Feb 03, 2025
pulisher
Feb 03, 2025

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Feb 03, 2025
pulisher
Jan 29, 2025

BRAF Inhibitors Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Jan 29, 2025
pulisher
Jan 28, 2025

Molecular Glue Degrader Market Key Players AnalysisC4 - openPR

Jan 28, 2025
pulisher
Jan 22, 2025

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 22, 2025
pulisher
Jan 20, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jan 20, 2025
pulisher
Jan 18, 2025

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jan 18, 2025
pulisher
Jan 17, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Jan 17, 2025
pulisher
Jan 14, 2025

C4 Therapeutics stock rises on portfolio update (CCCC:NASDAQ) - Seeking Alpha

Jan 14, 2025
pulisher
Jan 14, 2025

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology - The Manila Times

Jan 14, 2025
pulisher
Jan 14, 2025

C4 Therapeutics progresses with key 2025 clinical trials - Investing.com

Jan 14, 2025
pulisher
Jan 14, 2025

C4 Therapeutics Reveals Strong Cancer Drug Pipeline Progress, Sets Key 2025 Milestones - StockTitan

Jan 14, 2025
pulisher
Jan 14, 2025

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $10.67 Consensus PT from Brokerages - MarketBeat

Jan 14, 2025

C 4 Therapeutics Inc Stock (CCCC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$32.85
price up icon 1.51%
$81.36
price up icon 2.58%
$21.08
price down icon 1.36%
$372.83
price up icon 0.61%
biotechnology ONC
$238.11
price up icon 3.14%
$122.75
price up icon 2.44%
Cap:     |  Volume (24h):